The clinical potential of oligonucleotide therapeutics against pancreatic cancer

Kazuki Takakura, Atsushi Kawamura, Yuichi Torisu, Shigeo Koido, Naohisa Yahagi, Masayuki Saruta

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Although many diagnostic and therapeutic modalities for pancreatic cancer have been proposed, an urgent need for improved therapeutic strategies remains. Oligonucleotide therapeutics, such as those based on antisense RNAs, small interfering RNA (siRNA), microRNA (miRNA), aptamers, and decoys, are promising agents against pancreatic cancer, because they can identify a specific mRNA fragment of a given sequence or protein, and interfere with gene expression as molecular-targeted agents. Within the past 25 years, the diversity and feasibility of these drugs as diagnostic or therapeutic tools have dramatically increased. Several clinical and preclinical studies of oligonucleotides have been conducted for patients with pancreatic cancer. To support the discovery of effective diagnostic or therapeutic options using oligonucleotide-based strategies, in the absence of satisfactory therapies for long-term survival and the increasing trend of diseases, we summarize the current clinical trials of oligonucleotide therapeutics for pancreatic cancer patients, with underlying preclinical and scientific data, and focus on the possibility of oligonucleotides for targeting pancreatic cancer in clinical implications.

Original languageEnglish
Article number3331
JournalInternational journal of molecular sciences
Volume20
Issue number13
DOIs
Publication statusPublished - 2019 Jul 1

Fingerprint

oligonucleotides
Oligonucleotides
Pancreatic Neoplasms
cancer
RNA
decoys
Therapeutics
Antisense RNA
gene expression
Nucleotide Aptamers
MicroRNAs
Gene expression
Small Interfering RNA
therapy
drugs
fragments
proteins
Proteins
trends
Messenger RNA

Keywords

  • Antisense
  • Aptamer
  • Decoy
  • Oligonucleotide therapeutics
  • Pancreatic cancer
  • RNA interference

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

The clinical potential of oligonucleotide therapeutics against pancreatic cancer. / Takakura, Kazuki; Kawamura, Atsushi; Torisu, Yuichi; Koido, Shigeo; Yahagi, Naohisa; Saruta, Masayuki.

In: International journal of molecular sciences, Vol. 20, No. 13, 3331, 01.07.2019.

Research output: Contribution to journalReview article

Takakura, Kazuki ; Kawamura, Atsushi ; Torisu, Yuichi ; Koido, Shigeo ; Yahagi, Naohisa ; Saruta, Masayuki. / The clinical potential of oligonucleotide therapeutics against pancreatic cancer. In: International journal of molecular sciences. 2019 ; Vol. 20, No. 13.
@article{f1e2df62edc64055972154b32809d239,
title = "The clinical potential of oligonucleotide therapeutics against pancreatic cancer",
abstract = "Although many diagnostic and therapeutic modalities for pancreatic cancer have been proposed, an urgent need for improved therapeutic strategies remains. Oligonucleotide therapeutics, such as those based on antisense RNAs, small interfering RNA (siRNA), microRNA (miRNA), aptamers, and decoys, are promising agents against pancreatic cancer, because they can identify a specific mRNA fragment of a given sequence or protein, and interfere with gene expression as molecular-targeted agents. Within the past 25 years, the diversity and feasibility of these drugs as diagnostic or therapeutic tools have dramatically increased. Several clinical and preclinical studies of oligonucleotides have been conducted for patients with pancreatic cancer. To support the discovery of effective diagnostic or therapeutic options using oligonucleotide-based strategies, in the absence of satisfactory therapies for long-term survival and the increasing trend of diseases, we summarize the current clinical trials of oligonucleotide therapeutics for pancreatic cancer patients, with underlying preclinical and scientific data, and focus on the possibility of oligonucleotides for targeting pancreatic cancer in clinical implications.",
keywords = "Antisense, Aptamer, Decoy, Oligonucleotide therapeutics, Pancreatic cancer, RNA interference",
author = "Kazuki Takakura and Atsushi Kawamura and Yuichi Torisu and Shigeo Koido and Naohisa Yahagi and Masayuki Saruta",
year = "2019",
month = "7",
day = "1",
doi = "10.3390/ijms20133331",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "13",

}

TY - JOUR

T1 - The clinical potential of oligonucleotide therapeutics against pancreatic cancer

AU - Takakura, Kazuki

AU - Kawamura, Atsushi

AU - Torisu, Yuichi

AU - Koido, Shigeo

AU - Yahagi, Naohisa

AU - Saruta, Masayuki

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Although many diagnostic and therapeutic modalities for pancreatic cancer have been proposed, an urgent need for improved therapeutic strategies remains. Oligonucleotide therapeutics, such as those based on antisense RNAs, small interfering RNA (siRNA), microRNA (miRNA), aptamers, and decoys, are promising agents against pancreatic cancer, because they can identify a specific mRNA fragment of a given sequence or protein, and interfere with gene expression as molecular-targeted agents. Within the past 25 years, the diversity and feasibility of these drugs as diagnostic or therapeutic tools have dramatically increased. Several clinical and preclinical studies of oligonucleotides have been conducted for patients with pancreatic cancer. To support the discovery of effective diagnostic or therapeutic options using oligonucleotide-based strategies, in the absence of satisfactory therapies for long-term survival and the increasing trend of diseases, we summarize the current clinical trials of oligonucleotide therapeutics for pancreatic cancer patients, with underlying preclinical and scientific data, and focus on the possibility of oligonucleotides for targeting pancreatic cancer in clinical implications.

AB - Although many diagnostic and therapeutic modalities for pancreatic cancer have been proposed, an urgent need for improved therapeutic strategies remains. Oligonucleotide therapeutics, such as those based on antisense RNAs, small interfering RNA (siRNA), microRNA (miRNA), aptamers, and decoys, are promising agents against pancreatic cancer, because they can identify a specific mRNA fragment of a given sequence or protein, and interfere with gene expression as molecular-targeted agents. Within the past 25 years, the diversity and feasibility of these drugs as diagnostic or therapeutic tools have dramatically increased. Several clinical and preclinical studies of oligonucleotides have been conducted for patients with pancreatic cancer. To support the discovery of effective diagnostic or therapeutic options using oligonucleotide-based strategies, in the absence of satisfactory therapies for long-term survival and the increasing trend of diseases, we summarize the current clinical trials of oligonucleotide therapeutics for pancreatic cancer patients, with underlying preclinical and scientific data, and focus on the possibility of oligonucleotides for targeting pancreatic cancer in clinical implications.

KW - Antisense

KW - Aptamer

KW - Decoy

KW - Oligonucleotide therapeutics

KW - Pancreatic cancer

KW - RNA interference

UR - http://www.scopus.com/inward/record.url?scp=85069293364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069293364&partnerID=8YFLogxK

U2 - 10.3390/ijms20133331

DO - 10.3390/ijms20133331

M3 - Review article

C2 - 31284594

AN - SCOPUS:85069293364

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 13

M1 - 3331

ER -